Longitudinal Characterization of a Neutralizing and Total Antibody Response in Patients with Severe COVID-19 and Fatal Outcomes.

Autor:	Serna-Muñoz R; Departamento de Investigación en Tabaquismo y EPOC, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas INER, Mexico City 14080, Mexico.; Escuela Superior de Medicina, Instituto Politécnico Nacional, Mexico City 11340, Mexico., Hernández-Terán A; Departamento de Investigación en Tabaquismo y EPOC, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas INER, Mexico City 14080, Mexico., Soto-Nava M; CIENI Centre for Research in Infectious Diseases, National Institute of Respiratory Diseases, Mexico City 14080, Mexico., Tapia-Trejo D; CIENI Centre for Research in Infectious Diseases, National Institute of Respiratory Diseases, Mexico City 14080, Mexico., Ávila-Ríos S; CIENI Centre for Research in Infectious Diseases, National Institute of Respiratory Diseases, Mexico City 14080, Mexico., Mejía-Nepomuceno F; Departamento de Investigación en Tabaquismo y EPOC, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas INER, Mexico City 14080, Mexico., García E; Departamento de Unidad de Epidemiología Hospitalaria e Infectología, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas INER, Mexico City 14080, Mexico., Castillejos-López M; Departamento de Unidad de Epidemiología Hospitalaria e Infectología, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas INER, Mexico City 14080, Mexico., Higuera-Iglesias AL; Departamento de Unidad de Epidemiología Hospitalaria e Infectología, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas INER, Mexico City 14080, Mexico., Aquino-Gálvez A; Laboratorio de Biología Molecular, Departamento de Fibrosis Pulmonar, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas INER, Mexico City 14080, Mexico., Thirion-Romero I; Departamento de Investigación en Tabaquismo y EPOC, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas INER, Mexico City 14080, Mexico., Pérez-Padilla R; Departamento de Investigación en Tabaquismo y EPOC, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas INER, Mexico City 14080, Mexico., Aguilar-Faisal JL; Escuela Superior de Medicina, Instituto Politécnico Nacional, Mexico City 11340, Mexico., Vázquez-Pérez JA; Departamento de Investigación en Tabaquismo y EPOC, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas INER, Mexico City 14080, Mexico.
Jazyk:	angličtina
Zdroj:	Vaccines [Vaccines (Basel)] 2022 Dec 01; Vol. 10 (12). Date of Electronic Publication: 2022 Dec 01.
DOI:	10.3390/vaccines10122063
Abstrakt:	The host immune response to SARS-CoV-2 appears to play a critical role in disease pathogenesis and clinical manifestations in severe COVID-19 cases. Until now, the importance of developing a neutralizing antibody response in the acute phase and its relationship with progression to severe disease or fatal outcome among hospitalized patients remains unclear. In this study, we aim to characterize and compare longitudinally the primary humoral immune host response in the early stages of the disease, looking for an association between neutralization, antibody titers, infective viral lineage, and the clinical outcome in hospitalized and non-hospitalized patients. A total of 111 patients admitted at INER from November 2021 to June 2022 were included. We found that patients with negative or low neutralization showed a significant reduction in survival probability compared to patients with medium or high neutralization. We observed a significant decrease in the median of neutralization in patients infected with viral variants with changes in RBD of the spike protein. Our results suggest that developing an early and robust neutralizing response against SARS-CoV-2 may increase survival probability in critical patients.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu